One promising avenue is to use the variability in clinical characteristics of autism to build more focused hypotheses. For example, most children with autism show abnormalities within the first year of life. In contrast, about a quarter of autistic children seem to develop normally until about 15-24 months of age, when their development appears to regress. Geraldine Dawson at the University of Washington, who studies regressive autism, notes that distinguishing between early-and late-onset Alzheimer disease led to important breakthroughs and hopes that the same may be true for autism. A planned intramural program at the US National Institutes of Health will look at psychological, immune and other measures across regressive and non-regressive cases to examine what might precipitate the disease.
Improved understanding of phenotypic diversity is also guiding the search for autism risk genes. A subset of the symptoms of autism are often variably expressed in unaffected family members. The use of these endophenotypes increases the power of genetic analyses and may lead to identification of genetic homogeneities underlying individual traits. The hope, says Daniel Geschwind at UCLA, is to "take these genetic homogeneities and then work backward" to generate hypotheses about disease etiology, or about what types of gene-environment interactions may contribute to autism spectrum disorders.
In addition to interfering with such promising lines of research, the thimerosal controversy threatens to undermine the public's trust that scientists are committed to studying the problem. Overcoming this mistrust will require continued efforts from scientists to collaborate with the public. A good example is the US Department of Health and Human Services' Interagency Autism Coordinating Committee, which includes parents or legal guardians of autistic patients. These members represent the autism community and help guide policy decisions on autism research. Through this committee, the National Institutes of Health and other governmental agencies have developed partnerships for research and public education with national autism associations (http://www. nimh.nih.gov/autismiacc). Another successful collaborative effort is the Autism Genetic Resource Exchange (AGRE) program 4 founded by the Cure Autism Now organization, which has provided researchers with biomaterials from hundreds of families with autistic children.
In the end, McCormick may be correct that some supporters of the thimerosal hypothesis are unlikely to be swayed in their beliefs by anything short of finding the "silver bullet that causes autism." In the meantime, the absence of a clear mechanistic explanation should not be used to direct resources toward a single weak hypothesis. Parent groups should instead seek reassurance in continued collaboration with the scientific community as it moves forward in more promising directions.
